Where there is inflammation,treatment may reduce disability progression

Abstract

Get full access to this article

View all access options for this article.

References

Fisher

Lee

Nakamura

et al . Gray matter atrophy in multiple sclerosis: A longitudinal study. Ann Neurol 2008; 64: 255–265.

Broadley

Barnett

Boggild

et al . Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective: Part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists. J Clin Neurosci 2014; 21: 1847–1856.

Coles

Twyman

Arnold

et al . Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet 2012; 380: 1829–1839.

Cohen

Coles

Arnold

et al . Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet 2012; 380: 1819–1828.

Kalincik

Comparisons of therapies in different scenarios help complete the puzzle. Mult Scler 2018; 24: 694–695.

Lassmann

van Horssen

Mahad

Progressive multiple sclerosis: Pathology and pathogenesis. Nat Rev Neurol 2012; 8: 647–656.

Montalban

Hauser

Kappos

et al . Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017; 376: 209–220.

Hawker

O’Connor

Freedman

et al . Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66: 460–471.

Leray

Yaouanq

Le Page

et al . Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010; 133: 1900–1913.

10.

Lizak

Lugaresi

Alroughani

et al . Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. J Neurol Neurosurg Psychiatry 2017; 88: 196–203.

11.

Confavreux

Vukusic

Adeleine

Early clinical predictors and progression of irreversible disability in multiple sclerosis: An amnesic process. Brain 2003; 126: 770–782.

12.

Lublin

Reingold

Cohen

et al . Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology 2014; 83: 278–286.

13.

Hughes

Jokubaitis

Lugaresi

et al.

Contribution of inflammation to disability accrual in progressive-onset multiple sclerosis. JAMA Neurol in press.

14.

Confavreux

Vukusic

Moreau

et al . Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430–1438.

15.

Tremlett

Yousefi

Devonshire

et al . Impact of multiple sclerosis relapses on progression diminishes with time. Neurology 2009; 73: 1616–1623.

Where there is inflammation,treatment may reduce disability progression – Yes

Abstract

Get full access to this article

References